Ascendis moves forward with phase III drug

Ascendis Pharma has now reached the desired amount of patients for its phase III trial for the rare disease hypoparathyreoidism. The company has also achieved regulatory progress for the same drug in Japan.

Photo: Kevin Grønnemann

Ascendis Pharma can be satisfied with the progress it has made on several fronts regarding its new drug candidate.

The Danish, but US-listed, biotech company reports that it has recruited the required amount of patients for the company's phase III trial with the drug palopegteriparatide, also known as Transcon PTH, for the disease hypoparathyreoidism. The firm is also willing to let in patients who were prepped for the study in June, if they meet the required criteria.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs